

Updated Results of a Phase I, Open-Label Study of BCMA/CD19 Dual-Targeting FasTCAR-T GC012F for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Juan Du^{*1}, Weijun Fu¹, Hua Jiang¹, Baoxia Dong², Li Gao³, Li Liu⁴, Jian Ge⁵, Aili He⁶, Lu Li¹, Jing Lu¹, Xiequn Chen², Jia Liu⁷, Qi Zhang⁷, Lianjun Shen⁷, Lihong Weng⁷, Wenling Li⁷


¹Shanghai Chang Zheng Hospital, Shanghai, China, ²Xijing Hospital, Xi'an, ³Xinqiao Hospital, Chongqing, ⁴Tangdu Hospital,, Xi'an, ⁵The First Affiliated Hospital of Anhui Medical University, Hefei, ⁶The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, ⁷Gracell Biotechnologies Ltd, Shanghai, China







FasTCAR GC012F: BCMA/CD19 Dual-Targeting for Multiple Myeloma



#ASCO23

2023 **ASCO**

ANNUAL MEETING


BCMA: a proven target for MM

🕂 CD19:

expressed on majority of MM cells and subsets of **progenitor cells** ¹⁻³

- CD19+ progenitor cells make up a drug-resistant, colony-forming cell reservoir, which can be eliminated by CD19 targeting of GC012F
- Clinical study in r/r MM patients showed CD19 CAR-T provided PFS benefits in some patients ²


Targeting both antigens to maximize the elimination of MM plasma cells and CD19+ progenitor subsets and to drive DEEP and DURABLE response



Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

PRESENTED BY: Dr.Qiang

More effective elimination of MM progenitor cells



Boucher K, Parquet N, Widen R, et al. Clin Cancer Res. 2012;18(22):6155-6168.
 Garfall AL, Stadtmauer EA, Hwang WT, et al. Anti-CD19 CAR T cells with high-dose

melphalan and autologous stem cell transplantation for refractory multiple myeloma



JCI Insight. 2018;3(8):e120505 3. Hua Jiang, et al. ASH Annual Meeting 2020, 178

FasTCAR Platform: Next-Day Manufacturing


PRESENTED BY: Dr. Qiana

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

2023 **ASCO**

ANNUAL MEETING

#ASCO23



1) FasTCAR transforms the three primary production steps—activation, transduction and expansion—into a single "concurrent activation-transduction" step.

2 With minimized *ex vivo* culture time, FasTCAR-T cells are younger and shows enhanced proliferation and tumor clearance activities in preclinical studies, making possible the lower cell dosage and eliminating the need for *ex vivo* expansion. Expansion happens in patient body, an optimal condition.

ASCO[®] AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

GC012F DUAL CAR-T for RRMM : Study Design

Multicenter, open label, single-arm IIT¹ study (N=29) FPI October 2019, LPI January 2022; Pts continued to be assessed for response Data cut-off April 12th, 2023

Key Eligibility Criteria

- Relapsed/Refractory Multiple Myeloma²
- 3+prior lines of therapy and/or refractory to
- PI and IMiDs, primary refractory

#ASCO23

- Expected survival \geq 3 months

2023 **ASCO**

ANNUAL MEETING

Primary endpoint:


- Adverse Events

Secondary endpoints:

- ORR. BOR
- MRD assessment at pre-specified timepoints
- post CAR-T infusion
- PK/PD

Dose Levels

- DL1: 1x10⁵ cells/kg
- DL2: 2x10⁵ cells/kg
- DL3: 3x10⁵ cells/kg





PRESENTED BY: Dr. Qiana

GC012F DUAL CAR-T for RRMM : Baseline Characteristics


Baseline Characteristics	Total (N=29)	Baseline Characteristics	Total (N=29)
Median age, years (range)	57 (27-76)	Extramedullary plasmacytoma ≥ 1, n(%)	8 (28)
Male, n(%)	17 (59)	Median prior regimens, n (range)	5 (2-11)
Type of myeloma, n(%)		Median prior lines of therapy, n (range)	5 (2-9)
IgG	13 (45)	Prior auto-SCT, n(%)	11 (38)
IgA	6 (21)	Triple-exposed ^c , n(%)	28 (97)
IgD	5 (18)	PI refractory	27 (93)
Light chain	5 (18)	IMiD refractory	27 (93)
Median years since diagnosis (range)	4 (1-10)	anti-CD38 refractory	10 (34)
High-risk profileª, n(%)	<u>26 (90)</u>	Penta-exposed ^d , n(%)	18 (62)
Double-hit ^b , n(%)	3 (10)	Primary refractory, n (%)	3 (10)
ECOG, n(%)		Refractory to last therapy, n (%)	24 (83)
0&1	23 (79)	 ^a By mSMART 3.0; ^b By presence two of del(17p), t(4;14), t(14;16), t(14;20), gain 1q, or p53 mutation ^c PI, IMiD and any other therapies including anti-CD38 antibody; ^d ≥1 PI (Ixazomib and Bortezomib were approved in China), ≥1 IMiDs (only-Lenalid approved for MM in China) and ≥ 3 other anti-myeloma drugs of any other class. 	
2	4 (14)		
3	2 (7)		





2023 **ASCO**

ANNUAL MEETING




2023 **ASCO**

ANNUAL MEETING

- > ORR = 93.1% (27/29) patients
 - Best response achieved to date
 - 82.8% (24/29) MRD⁻ sCR
 - 89.6% (26/29) VGPR or better
- Median time to best response: 3 months (range, 0.9-15.3)
- Median DOR was 37.0 months (95% CI: 11.0 - NR)
- Median duration of follow up was 30.7 months (range: 14.6 – 43.6 months)





2023 **ASCO**

ANNUAL MEETING

- > 100% patients achieved MRD negativity
- 100% of evaluable pts assessed by Euroflow at sensitivity of 10⁻⁶ were MRD negative at Month 6 (n=15)
- > 78.6% of evaluable patients were MRD negative at Month 12



GC012F DUAL CAR-T for RRMM : PFS analysis

Subgroup	n	PFS, Median (95% CI, mo)	12-month PFS rate	36-month PFS rate
All patients	29	38.0 (11.8, NE)	69.0%	50.5%
sCR	24	38.0 (13.7, NE)	83.3%	61.0%
12-month sustained MRD negativity	10	NE (38.0, NE)	100%	100%
12-month sustained MRD negative CR	10	NE (38.0, NE)	100%	100%

- > mPFS is 38.0 months at data cutoff among a predominantly high risk patient population
- > Longer PFS was achieved in patients with 12-month sustained MRD negativity
- > 34% (10/29) of all GC012F-treated patients sustained MRD-negative for more than 12 months





GC012F DUAL CAR-T for RRMM : Safety Profile

N=29	All Grades, n (%)	Grade ≥3, n (%)	
Hematologic TEAEs* (≥ 25% All Grades)			
Neutropenia	23 (79)	23 (79)	
Lymphopenia	19 (66)	19 (66)	
Leukopenia	23 (79)	22 (76)	
Thrombocytopenia	22 (76)	16 (55)	
Anemia	14 (48)	10 (34)	
Non-Hematologic T	EAEs* (≥ 25% All Gr	ades)	
LDH increased	18 (62)	0 (0)	
Hypoalbuminemia	14 (48)	0 (0)	
AST increased	12 (41)	8 (29)	
Hypokalemia	19 (66)	4 (14)	
Hypophosphatemia	9 (31)	0 (0)	
Hypocalcemia	7 (24)	1 (3)	

N=29	CRS ¹ , n (%)	ICANS ² , n (%)
Grade 1	14 (48)	0 (0)
Grade 2	9 (31)	0 (0)
Grade 3	2 (7)	0 (0)
Grade 4-5	0 (0)	0 (0)

¹CRS treated with Tocilizumab, vasopressors and dexamethasone

CRS any grade	Median (days)	Range (days)
Time to onset	6	2-10
Duration	3	1-8

No new safety findings in the longer term follow-up

> No second primary malignancy reported

No any neurotoxicity observed

*AE were graded according to CTCAE v5.0, TEAE- treatment emergent adverse event, AST Aspartate Aminotransferase, LDH Lactase dehydrogenase, CRS – ¹Cytokine Release Syndrome - ASBMT consensus grading, ²ICANS – Immune Effector Cell-Associated Neurotoxicity Syndrome - ASBMT consensus grading




2023 **ASCO**

ANNUAL MEETING

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

GC012F DUAL CAR-T for RRMM : GC012F persistence



The CAR T cells were still detectable at 6 months (median value), indicating the sustained persistence of CAR T cell in RRMM patients

N=29, Cut-off data:2023-04-12; Grey lines: individuals; Red line: median; LLOQ (lower limit of quantification)= 30 copies/µgDNA






2023 **ASCO**

ANNUAL MEETIN

GC012F DUAL CAR-T for RRMM : Pharmacokinetics



No significant differences observed for AUC_{0-28d} between dose levels

#ASCO23

2023 **ASCO**

ANNUAL MEETING

AUC _{0-28d} of CAR-T in each dose level – Median		
	AUC _{0-28d} (copies*day/µg genomic DNA)	
	Median	Range
DL 1 (n= 2)	475434	396661- 554207
DL 2 (n=10)	470996	108069-7120348
DL 3 (n=17)	868235	57595-3166990
All patients (N=29)	553679	57595-7120348

AUC_{0-28d} of CAR-T in each dose level – Geometric Mean

	AUC _{0-28d} (copies*day/µg genomic DNA)		
	Geometric Mean	95% CI	
DL 1 (n= 2)	468863	56007-3925091	
DL 2 (n=10)	631540	272026-1466195	
DL 3 (n=17)	564843	284221-1039005	
All patients (N=29)	579515	331920- 758989	




PRESENTED BY: Dr. Qiang

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

GC012F DUAL CAR-T for RRMM : sBCMA

Serum BCMA (sBCMA) level declined sharply post CAR-T infusion

Median sBCMA level reached minimal at M2





#ASCO23

2023 **ASCO**

ANNUAL MEETING



PRESENTED BY: Dr. Qiana

Conclusions

- GC012F continues to show a favorable safety profile and no new safety findings in the longer term follow-up
- High overall responses rate ORR of 93.1% (27/29) and MRD- sCR rate of 82.8% (24/29) in a predominantly high risk population
- > MRD negativity achieved in all treated patients 100% (29/29), 100% (22/22) in patients tested by EuroFlow 10⁻⁶
- FAST, DEEP and DURABLE responses with median PFS 38.0m (95% CI: 11.8 NE) with patients still in followup
 - Patients with sustained MRD negativity had longer PFS
- BCMA/CD19 dual-targeting GC012F shows very promising activity in RRMM including High Risk patients and heavily pretreated patients with prior exposure to anti-38 mAb, PI, IMiDs
- GC012F IND phase I/II clinical trials in USA and China are starting



